What Is Tesamorelin? Benefits, Research & Safety
An FDA-approved growth hormone releasing hormone analogue used to reduce excess abdominal fat in HIV patients with lipodystrophy.
UK summary: FDA-approved in the US (Egrifta) for HIV-associated lipodystrophy with reasonable human evidence base for that specific indication. Not currently a UK-licensed medicine. Prohibited at all times under WADA S2 for athletes.
Quick Facts
Overview
Tesamorelin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
FDA-approved in the US (Egrifta) for HIV-associated lipodystrophy with reasonable human evidence base for that specific indication. Not currently a UK-licensed medicine. Prohibited at all times under WADA S2 for athletes.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not approved. Not available on NHS. May be accessible through specialist channels.
- EU: Not approved by EMA. Application was withdrawn.
- Notes: Tesamorelin (Egrifta) is FDA-approved in the US for HIV lipodystrophy. Not approved in UK or EU. Off-label use for anti-ageing or body composition is not supported by approved labeling.
05Approved medical uses
- HIV-associated lipodystrophy (FDA-approved as Egrifta in the US; not MHRA-licensed in the UK).
06Unapproved / promotional claims
- Targeted visceral-fat reduction for healthy adults.
- Anti-ageing growth-hormone restoration.
- Cognitive-decline reversal in older adults.
- Body-recomposition enhancement for bodybuilders.
07Common internet claims
- Marketed as an off-label fat-loss injection for cosmetic visceral-fat reduction.
- Sold by private 'anti-ageing' clinics as a GHRH analogue alternative to HGH.
- Promoted in bodybuilding stacks alongside testosterone, HGH, and insulin.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved for HIV lipodystrophy” | B | Yes | Moderate | Egrifta is FDA-approved for HIV-associated visceral lipodystrophy; this is not the same as UK MHRA approval, and it is not on the NHS. |
| “Targets visceral fat in healthy adults” | C | Limited | High | Outcome data are largely from the HIV-lipodystrophy population; generalising to healthy adults is not supported. |
| “Permitted in sport since it's a 'GHRH analogue'” | E | No | High | Prohibited at all times under WADA S2. |
| “Safer alternative to growth hormone” | E | No | High | Comparative-safety claims need comparative trials in the relevant population. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Hyperglycaemia and worsened insulin resistance with sustained use.
- Joint pain, peripheral oedema, carpal tunnel symptoms (GH-axis side effects).
- Injection-site reactions.
- Theoretical oncologic risk from sustained IGF-1 elevation.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not approved. Not available on NHS. May be accessible through specialist channels.
14EU legal position
Not approved by EMA. Application was withdrawn.
15What this page cannot tell you
- Whether a UK-purchased compounded tesamorelin contains the labelled peptide at the labelled concentration.
- Whether off-label cosmetic-fat-loss use carries the same safety profile as the licensed HIV-lipodystrophy indication.
- Long-term oncologic risk in healthy adults with no diagnosed deficiency.
- What the WADA in-competition exposure looks like — GH secretagogues are class-prohibited (S2).
16Last reviewed
17Citation quality score
18Research gaps
- No Phase 3 trials in non-HIV populations for cosmetic visceral-fat loss.
- Long-term oncologic surveillance in non-HIV populations absent.
- Body-composition outcome data in healthy adults limited.
- Combination-stack safety with HGH or insulin uncharacterised.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS or GMC-registered prescriber for clinically relevant weight reduction.
- GP and endocrinologist review for adult GH deficiency with formal testing.
- Resistance training plus structured aerobic exercise — the only evidence-based body-recomposition stack.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Tesamorelin a licensed UK medicine?
- If I have HIV-associated lipodystrophy, what UK access routes exist?
- If I'm an athlete, what is the WADA position?
- What licensed alternatives exist for the underlying issue I'm asking about?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Significant reduction in visceral adipose tissue (trunk fat)
- 2Modest improvements in trunk fat to limb fat ratio
- 3Improvements in some cardiovascular risk biomarkers
- 4Potential improvement in body image and quality of life
- 5Maintains physiological pulsatile GH release
- 6Research ongoing into cognitive benefits in older adults
Claim vs Evidence
How popular claims about Tesamorelin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved for HIV lipodystrophy” | B | Yes | Moderate | Egrifta is FDA-approved for HIV-associated visceral lipodystrophy; this is not the same as UK MHRA approval, and it is not on the NHS. |
| “Targets visceral fat in healthy adults” | C | Limited | High | Outcome data are largely from the HIV-lipodystrophy population; generalising to healthy adults is not supported. |
| “Permitted in sport since it's a 'GHRH analogue'” | E | No | High | Prohibited at all times under WADA S2. |
| “Safer alternative to growth hormone” | E | No | High | Comparative-safety claims need comparative trials in the relevant population. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 2 mg subcutaneous injection daily (approved dose) |
| Frequency | Once daily |
| Duration | Ongoing treatment required; effects reverse upon discontinuation |
| Notes | Tesamorelin (Egrifta) is FDA-approved only for HIV lipodystrophy. Off-label use lacks the same evidence base. Treatment requires ongoing administration. Should be prescribed and monitored by a physician. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (approved route)
| Half-Life | Stability |
|---|---|
| 26-38 minutes (as GHRH analogue) | Commercial product has defined stability; requires refrigeration |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (most common)
- Arthralgia (joint pain)
- Peripheral oedema
- Myalgia (muscle pain)
- Pruritus (itching)
- Paraesthesia
Rare Risks & Concerns
- Fluid retention syndromes
- Glucose intolerance or worsening diabetes
- Hypersensitivity reactions
- Potential effects on tumour growth (theoretical)
- Carpal tunnel syndrome
Contraindications
- Active malignancy
- Pregnancy and breastfeeding (Category X)
- Hypersensitivity to tesamorelin or mannitol
- Disruption of hypothalamic-pituitary axis (head trauma, surgery, etc.)
- Pituitary tumour or pituitary surgery
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved. Not available on NHS. May be accessible through specialist channels.
🇪🇺 European Union
Not approved by EMA. Application was withdrawn.
Clinical Studies Summary
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects or perturbation of glucose.
Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
Our review indicates that, based on the findings of the 10 included studies, GH axis treatments are effective in reducing VAT and increasing LBM in patients with HIV-associated lipodystrophy. However, clinicians must decide whether the attributed benefits are clinically significant, considering the costs and potential risks of GH axis treatments.
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
While tesamorelin reduced WC, the cognitive benefits did not significantly differ between groups. Recognizing the limitations of insufficient power and no placebo arm, this study suggests no clear benefit of short-term AO reduction with tesamorelin on NCI. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints.
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
The Massachusetts General Hospital has a royalty and license agreement with Theratechnologies for tesamorelin. SKG is the inventor on a pending patent, GHRH or Analogues Thereof For Use in Treatment of Hepatic Disease (application 16832128).
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Tesamorelin might be beneficial in people with HIV and NAFLD. Further studies are needed to determine the long-term effects of tesamorelin on liver histology.
Registered Trials & Regulatory Status
4 of 10 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Status: Recruiting · 120 participants · Hudson Biotech
Conditions: Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Status: Recruiting · 100 participants · Massachusetts General Hospital
Conditions: HIV-1-infection, Frailty, Impaired Physical Function
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Status: Completed · 51 participants · Massachusetts General Hospital
Conditions: Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
Status: Recruiting · 36 participants · Johns Hopkins University
Conditions: Peripheral Nerve Injuries
Body Composition and Adipose Tissue in HIV
Status: Terminated · 6 participants · Columbia University
Conditions: HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
Status: Completed · 73 participants · University of California, San Diego
Conditions: Mild Cognitive Impairment
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
Status: Withdrawn · National Institute of Nursing Research (NINR)
Conditions: Sleep Disorder, Traumatic Brain Injury
Tesamorelin Effects on Liver Fat and Histology in HIV
Status: Completed · 61 participants · Massachusetts General Hospital
Conditions: Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
Status: Withdrawn · Massachusetts General Hospital
Conditions: Abdominal Obesity
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Status: Terminated · 391 participants · Theratechnologies
Conditions: HIV
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Status: Terminated · 129 participants · Theratechnologies
Conditions: Diabetic Retinopathy, HIV
Egrifta Replacement and Sleep Disordered Breathing
Status: Withdrawn · Johns Hopkins University
Conditions: Lipodystrophy
Adverse event reports (FDA FAERS)
- depression3
- anxiety2
- lipodystrophy acquired2
- weight decreased2
- acute kidney injury1
- angiopathy1
- anhedonia1
- asthenia1
- basal cell carcinoma1
- chronic gastritis1
FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Tesamorelin?
Source research-grade Tesamorelin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Tesamorelin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Tesamorelin a licensed UK medicine?
- If I have HIV-associated lipodystrophy, what UK access routes exist?
- If I'm an athlete, what is the WADA position?
- What licensed alternatives exist for the underlying issue I'm asking about?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Related Peptides
AOD-9604
A modified fragment of human growth hormone specifically researched for its fat-metabolising properties without the growth-promoting effects of full HGH.
Learn moreCJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreSermorelin
A truncated form of natural GHRH that was the first GHRH analogue approved for clinical use, used for GH deficiency diagnosis and treatment.
Learn more